<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73754">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01739543</url>
  </required_header>
  <id_info>
    <org_study_id>PB_002</org_study_id>
    <nct_id>NCT01739543</nct_id>
  </id_info>
  <brief_title>A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer</brief_title>
  <official_title>A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexus Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexus Biomedical, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A REDUCTION IN C-SECTION RATES USING THE HEM-AVERT速 PERIANAL STABILIZER.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to evaluate an existing FDA approved device called the
      HEM-AVERT速 Perianal Stabilizer for its efficacy in reducing Cesarean births and/or reducing
      the second stage of labor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Reduce C-section Rate</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective (purpose) of this study is to evaluate the success rate of the HEM-AVERT速 device as a method of reducing C-section rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduce duration of 2nd stage of labor.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>A secondary objective is to evaluate the success rate of the HEM-AVERT速 device as a method of reducing the duration of second stage of labor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Complications; Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject receives Hem-Avert Device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject does not receive Hem-Avert Device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hem-Avert</intervention_name>
    <description>Application of Hem-Avert</description>
    <arm_group_label>Investigational</arm_group_label>
    <other_name>Hem-Avert Perianal Stabilizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is scheduled for vaginal delivery.

          -  Subject is willing and able to comply with the study plan as indicated by
             understanding and signing the Subject Informed Consent Form.

          -  Subjects' pre-natal examination indicates that this is to be a single birth delivery.

        Exclusion Criteria:

          -  Subject's scheduled for vaginal delivery with anticipated complications.

          -  Subject is unable to understand and sign the informed consent form.

          -  Subject does not deliver at study facility (hospital).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Burns, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unafilliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Niagara Falls Memorial Medical Center</name>
      <address>
        <city>Niagara Falls</city>
        <state>New York</state>
        <zip>14301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>November 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
